Focus Partners Advisor Solutions LLC Grows Position in Pfizer Inc. $PFE

Focus Partners Advisor Solutions LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 19.5% in the second quarter, Holdings Channel.com reports. The fund owned 145,419 shares of the biopharmaceutical company’s stock after purchasing an additional 23,735 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Pfizer were worth $3,502,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PFE. Brighton Jones LLC increased its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. United Bank grew its holdings in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares in the last quarter. Sei Investments Co. grew its holdings in Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after buying an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC increased its stake in Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Guggenheim decreased their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. Citigroup increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Finally, Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Trading Down 1.5%

Shares of PFE stock opened at $27.83 on Friday. The company has a market cap of $158.62 billion, a PE ratio of 36.62 and a beta of 0.34. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The stock’s 50 day simple moving average is $25.27 and its two-hundred day simple moving average is $26.24. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares benefited from renewed enthusiasm for cancer vaccines after Merck and Moderna reported positive melanoma-trial results for their personalized mRNA vaccine and Keytruda combination. The news has encouraged investors to reassess Pfizer’s own cancer-vaccine ambitions and broader mRNA exposure. Pfizer Stock Rises Wednesday: What’s Going On?
• Positive Sentiment: Pfizer’s obesity strategy remains a potential long-term catalyst. Investors are watching berobenatide, a possible monthly treatment intended to compete with leading GLP-1 drugs and help diversify revenue beyond legacy products. Pfizer’s Obesity Push
• Positive Sentiment: Pfizer’s high dividend yield and recent share performance are attracting income-oriented investors. Recent filings also indicate substantial hedge-fund buying, while unusually heavy call-option activity points to improving speculative sentiment. Yield Hunters and Hedge-Fund Buying
• Neutral Sentiment: Pfizer completed a real-world study evaluating Ibrance in advanced breast cancer. The study’s completion could provide useful evidence for the product, but investors are awaiting the data and any commercial implications. Pfizer’s Ibrance Study Update
• Negative Sentiment: Pfizer is settling thousands of Depo-Provera lawsuits alleging a link to intracranial meningiomas. While a settlement program may reduce litigation uncertainty, it also highlights potentially significant financial exposure and keeps legal risk overhanging the stock. Why Is Pfizer Settling Thousands of Legal Claims?
• Negative Sentiment: Investors remain focused on Pfizer’s patent cliff. New and acquired medicines may replace much of the revenue lost as older patents expire, but the transition leaves limited room for execution errors and raises concerns about longer-term growth. Pfizer Stock Is a Race Between New Drugs and Old Patents
• Negative Sentiment: Merck’s deeper investment in personalized cancer vaccines raises the competitive bar for Pfizer and could make it harder for Pfizer to establish a leading position in this emerging market. Merck Raises the Stakes for Pfizer’s Cancer Vaccine Ambitions

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.